Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONEO: Avelumab plus FLOT peri-operative therapy in resectable gastric or gastroesophageal junction cancer
2019-000782-21Phase 2Active
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Pathological complete response rate. Started Apr 2019; status: active.
02
Drugs
avelumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2019-000782-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000782-21.